Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Oral contraceptive use and clinical outcomes in patients with multiple sclerosis.
Serum level of interleukin-6 in Chinese patients with multiple sclerosis.
CCSVI and MS: a statement from the European Society of neurosonology and cerebral hemodynamics.
Trial watch: Chemotherapy with immunogenic cell death inducers.
Imaging of the spine at 3 tesla.
Cognitive impairment in neuro-Behcet's disease and multiple sclerosis: a comparative study.
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
The autonomic balance predicts cardiac responses after the first dose of fingolimod.
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV
Effect of Glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients.
Accuracy of StepWatch™ and ActiGraph Accelerometers for Measuring Steps Taken among Persons with Multiple Sclerosis.
Pregnancy in multiple sclerosis: a questionnaire study.
B-57The Temporal Onset of Cognitive Fatigue in Multiple Sclerosis.
Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders.
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits
FDA approves clinical trial of TDI-132 (Gilenya) in ALS patients
Modeling the heterogeneity of multiple sclerosis in animals.
The role of microbiome in central nervous system disorders.
The Role of Demyelination in Neuromyelitis Optica Damage: Diffusion-Tensor MR Imaging Study.
Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.
Can smoking aggravate my multiple sclerosis symptoms?
Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis.
Pages
« first
‹ previous
…
190
191
192
193
194
195
196
197
198
…
next ›
last »